IN2012DN06277A - - Google Patents

Info

Publication number
IN2012DN06277A
IN2012DN06277A IN6277DEN2012A IN2012DN06277A IN 2012DN06277 A IN2012DN06277 A IN 2012DN06277A IN 6277DEN2012 A IN6277DEN2012 A IN 6277DEN2012A IN 2012DN06277 A IN2012DN06277 A IN 2012DN06277A
Authority
IN
India
Prior art keywords
microalgal
extracellular bodies
heterologous
heterologous polypeptides
compositions
Prior art date
Application number
Other languages
English (en)
Inventor
Anne Cecile V BAYNE
James Casey Lippmeier
Kirk Emil Apt
Ross Eric Zirkle
Original Assignee
Dsm Ip Assets Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dsm Ip Assets Bv filed Critical Dsm Ip Assets Bv
Publication of IN2012DN06277A publication Critical patent/IN2012DN06277A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/02Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/145Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/12Unicellular algae; Culture media therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5258Virus-like particles
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16123Virus like particles [VLP]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151Methods of production or purification of viral material
    • C12N2760/16152Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01018Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Botany (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IN6277DEN2012 2009-12-28 2010-12-28 IN2012DN06277A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US29046909P 2009-12-28 2009-12-28
US29044109P 2009-12-28 2009-12-28
US41335310P 2010-11-12 2010-11-12
PCT/US2010/062276 WO2011090731A1 (fr) 2009-12-28 2010-12-28 Production de polypeptides hétérologues dans micro-algues, corps extracellulaires de micro-algues, compositions et leurs procédés de fabrication et leurs utilisations

Publications (1)

Publication Number Publication Date
IN2012DN06277A true IN2012DN06277A (fr) 2015-09-25

Family

ID=44307127

Family Applications (1)

Application Number Title Priority Date Filing Date
IN6277DEN2012 IN2012DN06277A (fr) 2009-12-28 2010-12-28

Country Status (9)

Country Link
US (3) US20110189228A1 (fr)
EP (3) EP3505632B1 (fr)
JP (4) JP6339548B2 (fr)
CN (2) CN102822343B (fr)
AU (4) AU2010343095B2 (fr)
CA (3) CA2785971C (fr)
EA (1) EA022841B1 (fr)
IN (1) IN2012DN06277A (fr)
WO (1) WO2011090731A1 (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI377253B (en) 2001-04-16 2012-11-21 Martek Biosciences Corp Product and process for transformation of thraustochytriales microorganisms
ES2752196T3 (es) * 2009-03-16 2020-04-03 Dsm Ip Assets Bv Producción de proteínas en microorganismos del filo Labyrinthulomycota
AR079767A1 (es) * 2009-12-28 2012-02-15 Merial Ltd Antigeno ndv (virus de la enfermedad de newcastle) recombinante y usos del mismo
IN2012DN06278A (fr) * 2009-12-28 2015-09-25 Dsm Ip Assets Bv
EP2444495A1 (fr) * 2010-10-20 2012-04-25 Algenics Sécrétion de polypeptides recombinants dans le support extracellulaire de diatomées
ES2678997T3 (es) 2011-03-07 2018-08-21 Dsm Nutritional Products Ag Microorganismos traustoquitridios modificados genéticamente
AU2012298713B2 (en) 2011-08-24 2017-11-23 Novozymes, Inc. Methods for obtaining positive transformants of a filamentous fungal host cell
BR112015001344A2 (pt) * 2012-07-24 2017-07-04 Bp Corp North America Inc xilose isomerases e seus usos
WO2014045191A2 (fr) * 2012-09-18 2014-03-27 Myko Tech Private Limited Polysaccharides extracellulaire provenant de labyrinthulomycetes ayant des activités antivirales à large spectre
US11464244B2 (en) 2014-10-02 2022-10-11 Evonik Operations Gmbh Feedstuff of high abrasion resistance and good stability in water, containing PUFAs
US20170295824A1 (en) 2014-10-02 2017-10-19 Evonik Degussa Gmbh Process for producing a pufa-containing biomass which has high cell stability
DK3200606T3 (da) * 2014-10-02 2021-06-21 Evonik Operations Gmbh Fremgangsmåde til fremstilling af et fodermiddel, der indeholder pufa'er, ved ekstrusion af en biomasse, der indeholder pufa'er, af typen labyrinthulomycetes
US11324234B2 (en) 2014-10-02 2022-05-10 Evonik Operations Gmbh Method for raising animals
WO2016140925A1 (fr) 2015-03-02 2016-09-09 Synthetic Genomics, Inc. Éléments de régulation provenant de micro-organismes labyrinthulomycetes
BR112018000690A2 (pt) * 2015-07-13 2018-09-18 MARA Renewables Corporation micro-organismo recombinante, e, métodos para preparar um micro-organismo de metabolização de xilose e para produzir óleo.
FR3038913B1 (fr) * 2015-07-17 2020-05-01 Fermentalg Biomasse de thraustochytrides, procede de culture et utilisations
EP3512948A4 (fr) * 2016-09-09 2020-05-13 Cornell University Administration d'acides nucléiques, de protéines et de petites molécules dans des corps vésiculaires vitreux
US10633454B2 (en) 2016-11-01 2020-04-28 Conagen Inc. Expression of modified glycoproteins and glycopeptides
CN109996810B (zh) * 2016-11-27 2023-08-22 特里同阿盖亚创新公司 从微藻中纯化重组骨桥蛋白的方法
WO2019173226A1 (fr) * 2018-03-05 2019-09-12 Synthetic Genomics, Inc. Organismes et procédés de production de glycomolécules à faible sulfatation
US20210243881A1 (en) 2018-06-27 2021-08-05 Sumitomo Electric Industries, Ltd. Original form body of flexible printed-wiring board, method of manufacturing flexible printed-wiring board, concentrated photovoltaic power generation module, and light emitting module
AU2019343188A1 (en) 2018-09-21 2021-05-20 Aufbau Medical Innovations Limited Compositions and methods for glaucoma
CN109161576B (zh) * 2018-09-26 2020-08-07 武汉中科光谷绿色生物技术有限公司 促进枯草芽孢杆菌发酵生产n-乙酰神经氨酸的方法
EP4063482A4 (fr) * 2019-11-21 2022-12-21 Panasonic Intellectual Property Management Co., Ltd. Cyanobacterie modifiee, procede de production de cyanobacterie modifiee et procede de production de proteine
IT201900024580A1 (it) 2019-12-18 2021-06-18 Consiglio Nazionale Ricerche Vescicole extracellulari da microalghe
CN111363045B (zh) * 2020-02-18 2021-12-17 厦门大学 一种流感、hiv嵌合蛋白及嵌合病毒疫苗的制备方法
CN111621471B (zh) * 2020-06-12 2022-03-11 成都世联康健生物科技有限公司 一种软组织胞外囊泡的提取方法及应用
JP2022028997A (ja) * 2020-07-31 2022-02-17 株式会社三洋物産 遊技機
CN112452506A (zh) * 2020-11-06 2021-03-09 五原县沃丰生物科技有限责任公司 一种培养基粉末的生产方法
US11175293B1 (en) 2021-01-04 2021-11-16 University Of Utah Research Foundation Rapid assay for detection of SARS-CoV-2 antibodies
WO2022269557A1 (fr) * 2021-06-24 2022-12-29 Reliance Industries Limited Algues recombinées et production de protéines de soie d'araignée à partir de ces algues recombinées
CN113698451B (zh) * 2021-08-02 2023-04-11 广东海洋大学 一种微藻多肽及其制备方法和应用
WO2023079113A1 (fr) 2021-11-05 2023-05-11 Sanofi Vaccins contre la grippe multivalents hybrides comprenant de l'hémagglutinine et de la neuraminidase et leurs procédés d'utilisation
KR20240105412A (ko) 2021-11-05 2024-07-05 사노피 파스퇴르 인크 재조합 헤마글루티닌과 뉴라미니다제를 포함하는 다가 인플루엔자 백신 및 이의 사용 방법
AR127808A1 (es) 2021-11-30 2024-02-28 Sanofi Pasteur Inc Vacunas contra el metapneumovirus humano
WO2023232976A1 (fr) * 2022-06-03 2023-12-07 Ags Therapeutics Sas Vésicules extracellulaires provenant de microalgues génétiquement modifiées contenant une cargaison chargée de manière endogène, leur préparation et utilisations
WO2023242605A1 (fr) 2022-06-14 2023-12-21 Támogatott Kutatócsoportok Irodája Vésicules extracellulaires destinées à être utilisées en thérapie
CN115992052A (zh) * 2022-11-18 2023-04-21 暨南大学 一种微藻类外泌体、其制备方法和应用
JP7546136B1 (ja) 2023-12-27 2024-09-05 ロート製薬株式会社 微細藻類由来の細胞外小胞を含有する組成物

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4659669A (en) * 1981-03-02 1987-04-21 Regents Of The Univ. Of California Microbial expression of human influenza hemagglutinin proteins
US4537769A (en) * 1982-04-06 1985-08-27 American Cyanamid Company Stabilization of influenza virus vaccine
US4752473A (en) * 1984-10-12 1988-06-21 The Regents Of The University Of California Expression of glycosylated human influenza hemagglutinin proteins
US5340742A (en) * 1988-09-07 1994-08-23 Omegatech Inc. Process for growing thraustochytrium and schizochytrium using non-chloride salts to produce a microfloral biomass having omega-3-highly unsaturated fatty acids
US5762939A (en) * 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
US5962298A (en) * 1994-01-11 1999-10-05 Vlaams Interuniversitair Instituut Voor Biotechnologie Influenza vaccine
WO1997020854A1 (fr) * 1995-12-05 1997-06-12 University Of Massachusetts Vesicules gazeuses de recombinaison et leur utilisation
US8003772B2 (en) * 1999-01-14 2011-08-23 Martek Biosciences Corporation Chimeric PUFA polyketide synthase systems and uses thereof
KR20000075076A (ko) * 1999-05-28 2000-12-15 최태진 형질전환된 미세조류를 이용하여 외래 단백질을 생산하는 방법
ATE376059T1 (de) * 2000-06-23 2007-11-15 Wyeth Corp Assemblierung von wildtyp und chimären influenzavirus-ähnlichen partikeln (vlps)
US7625756B2 (en) * 2000-06-28 2009-12-01 GycoFi, Inc. Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells
US7795002B2 (en) 2000-06-28 2010-09-14 Glycofi, Inc. Production of galactosylated glycoproteins in lower eukaryotes
EP1297172B1 (fr) 2000-06-28 2005-11-09 Glycofi, Inc. Procede de production de glycoproteines modifiees
US20060029604A1 (en) 2000-06-28 2006-02-09 Gerngross Tillman U Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
US20060257399A1 (en) * 2000-06-28 2006-11-16 Glycofi, Inc. Immunoglobulins comprising predominantly a Man5GIcNAc2 glycoform
AU2007249124B2 (en) * 2001-04-16 2012-05-17 Dsm Ip Assets B.V. Product and process for transformation of thraustochytriales microorganisms
TWI377253B (en) * 2001-04-16 2012-11-21 Martek Biosciences Corp Product and process for transformation of thraustochytriales microorganisms
AU2003213065A1 (en) * 2002-02-14 2003-09-04 Novavax, Inc. Novel insect cell line
EP1980268A2 (fr) * 2002-04-12 2008-10-15 Ilaria Capua Procédé de vaccination contre le virus de la gripper aviaire
US20060088909A1 (en) * 2002-05-17 2006-04-27 Compans Richard W Virus-like particles, methods of preparation, and immunogenic compositions
US7332299B2 (en) 2003-02-20 2008-02-19 Glycofi, Inc. Endomannosidases in the modification of glycoproteins in eukaryotes
US20070026076A1 (en) * 2003-02-24 2007-02-01 Tzyy-Choou Wu Molecular vaccines employing nucleic acid encoding anti-apoptotic proteins
KR20060017635A (ko) * 2003-06-05 2006-02-24 와이어쓰 홀딩스 코포레이션 베네쥬엘라 말 뇌염 바이러스 레플리콘 벡터 및파라믹소바이러스 단백질 항원을 포함하는 면역원성 조성물
ES2393492T3 (es) * 2004-05-25 2012-12-21 Medimmune, Llc Variantes de hemaglutinina y neuraminidasa de influenza
US8936930B2 (en) * 2004-08-05 2015-01-20 Ben-Gurion University Of The Negev Research And Development Authority Red microalgae expressing exogenous polypeptides and methods of generating and utilizing same
CA2594040A1 (fr) * 2005-01-06 2006-07-13 The Johns Hopkins University Interference arn bloquant l'expression de l'immunite potentialisee de proteines pro-apoptotiques induite par adn et des vaccins de cellules dendritiques transfectes
JP4796786B2 (ja) * 2005-04-28 2011-10-19 富士フイルム株式会社 ラビリンチュラ類を形質転換可能なベクター
JP4796787B2 (ja) * 2005-04-28 2011-10-19 富士フイルム株式会社 ラビリンチュラ類への遺伝子導入法
US9216212B2 (en) * 2005-08-05 2015-12-22 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
US20070042001A1 (en) * 2005-08-16 2007-02-22 Hawaii Biotech, Inc. Influenza recombinant subunit vaccine
SG169996A1 (en) * 2006-02-16 2011-04-29 Us Gov Health & Human Serv Antiviral agents and vaccines against influenza
CN106237316A (zh) * 2006-03-07 2016-12-21 法克斯因内特公司 包含血细胞凝集素的组合物、制造其的方法与使用其的方法
AU2007226510B2 (en) * 2006-03-15 2013-09-19 Dsm Ip Assets B.V. Polyunsaturated fatty acid production in heterologous organisms using pufa polyketide synthase systems
US8778353B2 (en) * 2006-05-01 2014-07-15 Technovax, Inc. Influenza virus-like particle (VLP) compositions
EP2044224A4 (fr) * 2006-07-27 2011-04-13 Ligocyte Pharmaceuticals Inc Particules de type virus chimérique
WO2008024844A2 (fr) * 2006-08-22 2008-02-28 The Johns Hopkins University Combinaisons thérapeutiques anticancers
CA2615372A1 (fr) * 2007-07-13 2009-01-13 Marc-Andre D'aoust Particules semblables au virus grippal a comprenant de l'hemagglutinine
DK2610345T3 (en) * 2007-11-27 2015-12-07 Medicago Inc RECOMBINANT INFLUENZA VIRUS SIMULAR PARTICULARS (VLPS) MADE IN TRANSGENE PLANTS THAT EXPRESS HEMAGGLUTININ
EP2090648A1 (fr) * 2008-02-12 2009-08-19 Institut Francais de Recherche pour l'Exploitation de la Mere(Ifremer) Production de polypeptides glycosylés dans des microalgues
KR20090096890A (ko) * 2008-03-10 2009-09-15 전남대학교산학협력단 대장균에서 조류인플루엔자 바이러스의 뉴라미니다제 n1을발현하기 위한 벡터 및 방법, 이의 사용방법, 및뉴라미니다제 저해제
FR2928926B1 (fr) * 2008-03-18 2015-08-21 Centre Nat Rech Scient Polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leur utilisation pour la production de compositions immunogenes
US8252106B2 (en) * 2008-03-19 2012-08-28 Momentive Specialty Chemicals Inc. Modifier for concrete and cement formulations and methods of preparing the same
ES2752196T3 (es) 2009-03-16 2020-04-03 Dsm Ip Assets Bv Producción de proteínas en microorganismos del filo Labyrinthulomycota
AR079767A1 (es) * 2009-12-28 2012-02-15 Merial Ltd Antigeno ndv (virus de la enfermedad de newcastle) recombinante y usos del mismo
IN2012DN06278A (fr) * 2009-12-28 2015-09-25 Dsm Ip Assets Bv

Also Published As

Publication number Publication date
AU2017202195B2 (en) 2019-04-18
EP2519635B1 (fr) 2018-11-21
US20150110826A1 (en) 2015-04-23
EP4130273C0 (fr) 2024-06-12
US20200063174A1 (en) 2020-02-27
EP4130273A1 (fr) 2023-02-08
JP2013515503A (ja) 2013-05-09
CA2785971C (fr) 2019-02-12
JP6666950B2 (ja) 2020-03-18
AU2017202195A1 (en) 2017-04-20
AU2010343095A1 (en) 2012-08-09
JP2016047055A (ja) 2016-04-07
AU2010343095B2 (en) 2017-01-05
WO2011090731A1 (fr) 2011-07-28
JP2023101420A (ja) 2023-07-20
AU2019206054B2 (en) 2022-03-10
EP4130273B1 (fr) 2024-06-12
EP3505632B1 (fr) 2022-08-03
AU2022203980A1 (en) 2022-06-30
EA022841B1 (ru) 2016-03-31
JP5838496B2 (ja) 2016-01-06
JP2020096635A (ja) 2020-06-25
CN107746869A (zh) 2018-03-02
AU2019206054A1 (en) 2019-08-08
CN102822343B (zh) 2017-10-20
EP3505632A1 (fr) 2019-07-03
JP2018121660A (ja) 2018-08-09
CA2785971A1 (fr) 2011-07-28
EP2519635A4 (fr) 2013-06-26
CA3028175A1 (fr) 2011-07-28
CA3028175C (fr) 2022-05-24
CA3153553A1 (fr) 2011-07-28
JP6339548B2 (ja) 2018-06-06
EA201290567A1 (ru) 2013-02-28
US20110189228A1 (en) 2011-08-04
CN102822343A (zh) 2012-12-12
EP2519635A1 (fr) 2012-11-07

Similar Documents

Publication Publication Date Title
IN2012DN06277A (fr)
EP3358000A3 (fr) Cellules fongiques filamenteuses déficientes en protéases et leurs procédés d'utilisation
EP2504360A4 (fr) Anticorps monomère fc
IN2014CN02100A (fr)
SG10201805291TA (en) Production of heterodimeric proteins
IN2015DN01404A (fr)
MX2011011911A (es) Polipeptidos de amilasa.
IN2012DN06278A (fr)
PH12014501912A1 (en) Cx3cr1-binding polypeptides
IN2014DN00161A (fr)
IN2013MN01394A (fr)
MX2015005384A (es) Miembros de union para il-1 beta.
MX347771B (es) Polipeptidos antibacterianos quimericos.
SG10201901713RA (en) Extracellular matrix compositions
MX349301B (es) Polipéptidos de somatotropina bovina modificados y sus usos.
HK1250743A1 (zh) 表達載體組織、新的生產用細胞產生方法及其在重組產生多肽中的用途
MY180183A (en) Methods and compositions for preventing norleucine misincorporation into proteins
IN2014CN02963A (fr)
MX2011012623A (es) Construcciones de casb7439.
MY194277A (en) Omega-hydroxylase-related fusion polypeptide variants with improved properties
EP2902413A4 (fr) Polypeptide, composition d'échafaudage, composition de restauration de tissu cartilagineux, composition de culture de cellules cartilagineuses et composition de promotion de la production de glycosaminoglycane
SI2839003T1 (sl) Zmanjšanje tvorbe amidiranih aminokislin v celičnih linijah za izražanje proteinov
IN2012DN03358A (fr)
EP2408926A4 (fr) Production de protéines de recombinaison dans des ciliés et leurs utilisations
EP2297331A4 (fr) Procédés et compositions pour la production de protéine de recombinaison dans des cellules mammaliennes exprimant hbx